{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia","description":"News from ASH 2020:  No benefit from tranexamic acid prophylaxis in blood cancers: https:\/\/bit.ly\/2K3Mah1 \u2018Practice changing\u2019: Ruxolitinib as second-line in chronic GVHD: https:\/\/bit.ly\/3gT4kyg&amp;nbsp; Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https:\/\/bit.ly\/381f1ut Five-minute SC injection of daratumumab in RRMM: https:\/\/bit.ly\/3gKuZgx  Email Blood &amp;amp; Cancer at podcasts@mdedge.com &amp;nbsp; ","author_name":"Blood &amp; Cancer","author_url":"https:\/\/www.mdedge.com\/podcasts\/blood-cancer","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/17186720\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/984545\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/17186720"}